MY192035A - Orally administered corticosteroid compositions - Google Patents

Orally administered corticosteroid compositions

Info

Publication number
MY192035A
MY192035A MYPI2016701126A MYPI2016701126A MY192035A MY 192035 A MY192035 A MY 192035A MY PI2016701126 A MYPI2016701126 A MY PI2016701126A MY PI2016701126 A MYPI2016701126 A MY PI2016701126A MY 192035 A MY192035 A MY 192035A
Authority
MY
Malaysia
Prior art keywords
orally administered
administered corticosteroid
corticosteroid compositions
compositions
individual
Prior art date
Application number
MYPI2016701126A
Inventor
Gopi M Venkatesh
Stephen Perrett
Fredric Jay Cohen
Original Assignee
Adare Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adare Pharmaceuticals Inc filed Critical Adare Pharmaceuticals Inc
Publication of MY192035A publication Critical patent/MY192035A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Orally administered corticosteroid compositions and methods for treating a condition associated with inflammation of the gastrointestinal tract in an individual, comprising administering to an individual said orally administered corticosteroid composition are disclosed.
MYPI2016701126A 2016-03-29 2010-09-30 Orally administered corticosteroid compositions MY192035A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201661247642P 2016-03-29 2016-03-29

Publications (1)

Publication Number Publication Date
MY192035A true MY192035A (en) 2022-07-24

Family

ID=82848574

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2016701126A MY192035A (en) 2016-03-29 2010-09-30 Orally administered corticosteroid compositions

Country Status (1)

Country Link
MY (1) MY192035A (en)

Similar Documents

Publication Publication Date Title
MX2020007226A (en) Orally administered corticosteroid compositions.
HK1218560A1 (en) Compositions and methods
MX2013008851A (en) Compostions and methods for treating chronic inflammation and inflammatory diseases.
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
WO2011113013A3 (en) Methods and compositions for treating viral or virally-induced conditions
CA2868551C (en) Methods and compositions for treating inflammation
MX2012007806A (en) Pharmaceutical compositions for oral administration of insulin peptides.
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
MX2011007589A (en) Treatment of a cancer using a combination of bendamustine and an anti-cd20 antibody.
WO2012092458A3 (en) Compositions comprising placental stem cells and platelet rich plasma, and methods of use thereof
WO2009063222A3 (en) Solid compositions
MX2015009058A (en) Compositions and methods for treating chronic inflammation and inflammatory diseases.
WO2011104652A3 (en) Veterinary compositions
MX2011011596A (en) Perifosine and capecitabine as a combined treatment for cancer.
MY165888A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
MX363549B (en) Antidiabetic solid pharmaceutical compositions.
MX2015001488A (en) Treating inflammation using serelaxin.
MX348147B (en) Bisarylsulfonamides useful in the treatment of inflammation and cancer.
HK1204962A1 (en) Cyclodextrin-based polymers for therapeutic delivery
WO2011130692A3 (en) Androgen induced oxidative stress inhibitors
WO2013037985A8 (en) Pharmaceutical combinations including anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
WO2014170820A3 (en) A pharmaceutical combination for treating tuberculosis
WO2011161465A3 (en) Composition for treatment of skin
TR201006225A1 (en) Double-release dexlansoprazole oral tablet compositions
UA59562U (en) method for preventing the progression of inflammation in the liver in patients with nonalcoholic steatohepatitis